ResMed (RMD) stock-based compensation was $104M in FY2026 (+14% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2026
$104M
+14%
2025
$92M
+14%
2024
$80M
+13%
2023
$71M
+9%
2022
$65M
+2%
2021
$64M
+11%
2020
$58M
+11%
2019
$52M
+8%
2018
$48M
+5%
2017
$46M
-1%
2016
$46M
-3%
2015
$48M
+10%
2014
$43M
+14%
2013
$38M
+25%
2012
$31M
-1%
2011
$31M
+4%
2010
$30M
+17%
2009
$26M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q2 2026
$27M
Q1 2026
$27M
Q4 2025
$29M
Q3 2025
$21M
Q2 2025
$25M
Q1 2025
$24M
Q4 2024
$23M
Q3 2024
$20M
Q2 2024
$21M
Q1 2024
$20M
Q4 2023
$20M
Q3 2023
$19M
Source: RMD on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.